Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.7% |
| 2 | Financials | 7.47% |
| 3 | Consumer Discretionary | 6.7% |
| 4 | Communication Services | 6.02% |
| 5 | Healthcare | 4.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CIM
2776
Chimera Investment
CIM
$991M
| $2.4M | ﹤0.01% |
193,268
+34,132
| +21% | +$434K |
|
2777
Byline Bancorp
BY
$1.78B
| $2.4M | ﹤0.01% |
82,366
+13,646
| +20% | +$383K |
|
2778
Root
ROOT
$748M
| $2.4M | ﹤0.01% |
33,237
+16,786
| +102% | +$1.34M |
|
2779
Ascendis Pharma A/S
ASND
$16.8B
| $2.4M | ﹤0.01% |
11,244
+462
| +4% | +$95.4K |
|
2780
Horizon Bancorp
HBNC
$1.05B
| $2.4M | ﹤0.01% |
141,362
+11,609
| +9% | +$192K |
|
2781
Orrstown Financial Services
ORRF
$850M
| $2.39M | ﹤0.01% |
67,598
+19,821
| +41% | +$692K |
|
2782
Euronet Worldwide
EEFT
$2.66B
| $2.39M | ﹤0.01% |
31,447
-14,042
| -31% | -$1.09M |
|
2783
B2Gold
BTG
$6.88B
| $2.39M | ﹤0.01% |
530,568
-996
| -0.2% | -$4.64K |
|
2784
United Parks & Resorts
PRKS
$2.01B
| $2.39M | ﹤0.01% |
65,847
-15,645
| -19% | -$650K |
|
2785
GCM Grosvenor
GCMG
$2.82B
| $2.38M | ﹤0.01% |
210,430
+14,608
| +7% | +$167K |
|
2786
Blue Bird Corp
BLBD
$2.04B
| $2.38M | ﹤0.01% |
50,678
+2,039
| +4% | +$107K |
|
2787
Barrett Business Services
BBSI
$756M
| $2.38M | ﹤0.01% |
65,742
+7,099
| +12% | +$272K |
|
|
HSHP
2788
Himalaya Shipping
HSHP
$703M
| $2.37M | ﹤0.01% |
260,780
+161,378
| +162% | +$1.36M |
|
|
NGD
2789
DELISTED
New Gold Inc
NGD
| $2.37M | ﹤0.01% |
272,219
-887,505
| -77% | -$6.68M |
|
2790
German American Bancorp
GABC
$1.91B
| $2.37M | ﹤0.01% |
60,479
+9,360
| +18% | +$369K |
|
2791
Regenxbio
RGNX
$720M
| $2.37M | ﹤0.01% |
164,421
-61,519
| -27% | -$767K |
|
2792
iShare MSCI Eurozone ETF
EZU
$9.96B
| $2.37M | ﹤0.01% |
36,906
+23,229
| +170% | +$1.46M |
|
2793
Under Armour
UAA
$2.26B
| $2.37M | ﹤0.01% |
475,890
-1,213,829
| -72% | -$5.62M |
|
2794
DoubleVerify
DV
$2.04B
| $2.36M | ﹤0.01% |
206,726
+34,712
| +20% | +$383K |
|
|
BBUC
2795
Brookfield Business Corp Class A Subordinate Voting Shares
BBUC
$5.93B
| $2.35M | ﹤0.01% |
65,506
+8,760
| +15% | +$307K |
|
2796
PUT
Dollar General
DG
$26.4B
| $2.35M | ﹤0.01% |
17,700
| – | – |
|
2797
Invesco Aerospace & Defense ETF
PPA
$8.68B
| $2.35M | ﹤0.01% |
+15,000
| New | +$2.31M |
|
2798
Costamare
CMRE
$1.71B
| $2.35M | ﹤0.01% |
148,753
+52,716
| +55% | +$728K |
|
2799
PUT
Cummins
CMI
$87.8B
| $2.35M | ﹤0.01% |
4,600
| – | – |
|
2800
Camping World
CWH
$659M
| $2.35M | ﹤0.01% |
241,230
-36,637
| -13% | -$454K |
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $49.1B in Q4 2025, closing 641 positions and reducing 1,715 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 20% a quarter earlier, followed by Financials and Consumer Discretionary.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.